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Abstract 
The variable regions of the camel heavy chain antibody, also known as nanobody is the smallest antibody with 
antigen-binding efficiency. CTGF is considered important during extracellular matrix deposition which was involved 
in the pathogenesis of fibrosis related diseases. There are several anti-CTGF-C nanobody drugs under developing in 
pharmacy. In this study, we described the screening of a novel anti-CTGF-C nanobody from the peripheral blood of 
immunized camel by phage display. The screened nanobody was further expressed and purified from E. coli cells. A 
sophisticated dialysis–dilution method was designed for the in vitro refolding of the nanobody. The results showed 
that the expressed nanobody was consisted of 135 amino acid and mainly expressed as inclusion body in E. coli cells. 
The dialysis–dilution method was very effective and the recovery rate of the renaturation was more than 80 %. The 
ELISA result suggested the nanobody had been well refolded showing a superior CTGF binding activity to the com-
mercial mouse anti-CTGF-C mAb. In conclusion, the anti-CTGF-C nonobody had been successfully screened by phage 
display. The dialysis–dilution refolding method was very effective and the recovery rate reached over 80 %.
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Introduction
Connective tissue growth factor, also known as CCN2 
is the second member of the CCN family which were 
characterized of four discrete modules, namely insulin-
like growth factor binding protein-like (IGFBP), von 
Willebrand factor type C repeat (VWC), thrombospon-
din type 1 repeat (TSP1) and C-terminal cystine-knot 
(CT) modules (Leask and Abraham 2006; Kubota and 
Takigawa 2007). The full-length CCN2 is a 38-kDa pro-
tein with a tetramodular structure. These modules are 
commonly characterized of cysteine–rich domains and 
are highly interactive with numerous cellular factors, 
such as such as fibronectin and heparin sulfate pro-
teoglycans, extracellular signaling molecules, and cell 
surface proteins (Holbourn et  al. 2008). CTGF expres-
sion is spatio-temporally restricted and is involved in 
multiple physiological events, such as postnatal olfac-
tory development, epithelial–mesenchymal transition 
(EMT) (Mosher and Adams 2012; Aguiar et  al. 2014; 
Kubota and Takigawa 2015) and islets formation in 
the pancreas. In spite of its physiological contribution, 
CTGF is most widely recognized as a profibrotic fac-
tor. In most fibrotic disorders, CTGF acts as a down-
stream effector of TGF-β to promote the phenotypic 
conversion of fibroblastic cells to the myofibroblasts 
that conduct fibrosis (Ihn 2002; Dendooven et al. 2011). 
Besides, CTGF disorder is found in a variety of malig-
nancy. CTGF is produced by tumor cells and acts on 
themselves through a paracrine manner promoting the 
tumor invasion and metastasis (Chu et al. 2008; Aguiar 
et al. 2014).
The camel heavy chain antibody consisted of only one 
heavy chain including a variable domain and two con-
stant regions of CH2 and CH3 was first reported by 
Hamers–Casterman and his colleagues in 1993 (Ham-
ers–Casterman et  al. 1993). The variable domain of the 
camel heavy chain (VHH) also known as nanobody is the 
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smallest antibody with antigen binding efficiency and is 
considered valuable in clinic due to its high tissue pen-
etration efficiency (Kong et al. 2014). From a biotechnol-
ogy view, nanobody is an ideal subject and is considered 
superior to the conventional antibodies such as IgG and 
scFv. Nanobody is easy for heterogeneous expression in 
eukaryotic or prokaryotic systems (van der Vaart 2002; 
Mizukami et  al. 2015). Nanobody possessing multiple 
disulfide bonds is more stable and it could be stored in 
RT. Unlike scFv which always self-aggregates, nanobody 
is more soluble after heterogeneous expression (Kong 
et al. 2014).
The C-terminal module of CTGF is reported of poten-
tial to bind integrin receptors and to promote cellular 
adhesion and migration independently (Gao and Brig-
stock 2004; Hoshijima et  al. 2006). In this study, we 
aimed to screen the VHH gene from the peripheral blood 
of a camel immunized with CTGF-C proteins by phage 
display, and then to express the VHH nanobody in E. coli 
cells as inclusion body. The expressed nanobody required 
renaturation and the in vitro activity was further investi-
gated by ELISA after purification.
Materials and methods
Strain, Cell and DNA
Escherichia coli BLR (DE3) and BL21 (DE3) (New Eng-
land Biolabs, Beverly, MA, USA) served as expres-
sion hosts. The pET22b(+)-anti-CTGF-VHH plasmid 
was used as the expressing vectors (GeneBank no. 
KX428017). The DNA primers were ordered from Gen-
eray Co., Ltd (Shanghai, China).
Reagents
The CTGF-C protein was provided by ZhongDa Hospi-
tal (Nanjing, China). The CTGF/CCN2 standard sample 
was purchased from Peprotech (London, United King-
dom). LuriaBertani (LB) medium (w/v) was used for E. 
coli culture. Restriction enzymes NcoI and NotI were pur-
chased from New England Biolabs. Mouse anti-CTGF-C 
monoclonal antibody was purchased from R&D (USA). 
Horseradish peroxidase-conjugated mouse anti-human 
CTGF polyclonal antibody were purchased from Abnova 
(USA). Nickle affinity column and Sephadex G-50 were 
purchased from Novagen (Madison, Wisconsin, USA). 
Other chemicals used in this study were of analytical or 
higher grade.
Camel immune
A healthy 12-month-old male camel was first immunized 
with 200 mg recombinant CTGF through muscular injec-
tion, and the second and third injections were taken at 
1 and 6 months later, respectively. Peripheral blood was 
collected at the 7th month from the jugular vein.
RNA extraction and construction of camel VHH Antibody 
phage pool
A volume of 100 ml peripheral blood was centrifuged at 
1000  rpm and the blood cells were collected. Red cells 
were removed by washing the cells in red cell lysate 
buffer for 4 times and the remains were collected for 
RNA extraction (Tanha et al. 2002; Miyazaki et al. 2015).
The construction of VHH antibody library of CTGF 
was schematically represented in Fig.  1. The total RNA 
was extracted from 3 × 107 leukocytes by the QIAGEN 
RNA Blood kit (QIAGEN, Mississauga, Canada) accord-
ing to the recommended protocol. The VHH repertoire 
was retrieved with reverse transcription followed by two 
rounds of nested PCR (Tanha et al. 2002; Fagerlund et al. 
2014). In brief, RNA-derived cDNA was obtained by 
reverse transcription with an oligo-dT primer and 10 μg 
RNA as the template. The obtained cDNAs were sub-
jected to another two rounds of PCR for amplification. 
There were two different forms of cDNAs, of which one 
contained only VHH and CH2 regions and the other con-
tained an extra CH1 region. The primers for each PCR 
were summarized in Table 1. The PCR product from each 
round was purified from agarose gel. The VHH DNA rep-
ertoire was analyzed by sequencing.
About 4.1 μg purified VHH PCR fragments and 16.6 μg 
of linearized pHEN2 vector were used for ligation. 
VHH DNAs were digested with NotI and NcoI and then 
inserted into phage M13 vector which was pre-digested 
with NotI and NcoI. The constructed recombinant vector 
was applied to ~1015 E. coli cells for transformation with 
electroporing, and the E. coli cells were then cultured in 
LB medium for 24 h at 37  °C. Phage particles were pre-
cipitated by addition of sterile 5  % PEG2000, and then 
resuspended in sterile PBS for bio-banning.
Bio‑panning of phage
A 96-wells plate was coated overnight at 4 °C with 20 μg/
ml human CTGF C-terminal domain (CTGF/C, Pepro-
Tech, Asia) dissolved in 0.05 M NaHCO3 (pH8.6) (Nunc) 
(100 μl/well) followed an incubation with 5 % BSA. The 
phage was diluted to 3 × l012 pfu/ml with TBS containing 
0.1 % Tween-20 and 100 μl of the dilution was then added 
to each well of the plate with slightly shaking at an inter-
val of 5 min at 37 °C for 1 h. The wells were washed with 
0.1–0.5 % Tween-20/TBS to remove the unbound phages. 
The bound phages were retrieved by adding 0.2 M Gly-
cine–HCl (pH2.2) containing 0.5  % BSA, and immedi-
ately neutralized with 1 M Tris–HCl (pH9.1).
The eluted phage with affinity to CTGF were added 
into exponentially growing E. coli BLR cells in 10 ml LB 
medium and stood for 30 min at 37 °C. Forty millilitre LB 
containing 100  mg/ml of ampicillin and 1  % of glucose 
was added and the flask was incubated at 37  °C for 2 h. 
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Wild-type phage VCSM13 (Invitrogen Corp.) of 1 × 1012 
pfu was added and incubated for another 4.5 h at 37 °C. 
The phage was collected from the supernatant after cen-
trifugation at 8000  rpm for 15  min at 4  °C. The phages 
were further purified for the next round of bio-panning 
by precipitation with 1/6 volume of polyethylene glycol 
8000 (PEG8000)/2.5  M NaCl. Three rounds of bio-pan-
ning were applied with the selection strength increased 
in each round as shown in Table 2.
Phage ELISA and DNA sequencing
A small aliquot of the the purified phages after bio-pan-
ning was serially diluted in exponentially growing BLR 
cells to determine the titer. Two hundred microliters of 
the diluted cells were mixed with 3 ml of 0.7 % agarose 
in LB/IPTG/X-gal at 45 °C and immediately poured onto 
three plates prewarmed to 37  °C. Plates were incubated 
overnight at 37 °C and plaques were counted.
Individual plaque was randomly picked out, amplified 
and subjected to phage enzyme-linked immunosorbent 
assay (ELISA). In brief, the eluted phage with affinity to 
CTGF were added into exponentially growing BLR cells 
in 1 ml LB medium and stood for 30 min at 37 °C. Four 
millilitre LB containing 100 mg/ml of ampicillin and 1 % 
of glucose was added and the flask was incubated at 37 °C 
for 2 h. Wild-type phage VCSM13 (Invitrogen Corp.) of 
1 × 1011 pfu was added and incubated for another 4.5 h 
at 37  °C. The phage was collected from the supernatant 
after centrifugation at 8000 rpm for 15 min at 4 °C. The 
phage was further purified by precipitation with 1/6 vol-
ume of polyethylene glycol 8000 (PEG8000)/2.5 M NaCl, 
and resuspended in 0.5 ml of PBS (pH7.4). An aliquot of 
50 μl resuspension was added to each well of a microti-
ter plate that was pre-coated with 1 μg/ml of CTGF dis-
solved in 0.05 M NaHCO3 (pH 8.6) and blocked by 1 % 
BSA. After incubated at room temperature for 2  h, the 
plate was washed 15 times with 2.0  % Tween-20/TBS. 
The bound phages were detected by adding 50  μl HRP-
conjugated anti-M13 antibody (Pharmacia, diluted 5000 
times with PBS) followed by an incubation of 1 h. A vol-
ume of 50  μl 3,3′,5,5′-tetramethylbenzidine (TMB, San-
gon, China) of 100  μg/ml was added to each well and 
incubated for 10 min. H2SO4 (1 M, 50 μl/well) was added 
and the plate was sent for colorimetry to measure the 
absorbance at 450 and 620 nm (Alisei, Italy). Fifteen colo-
nies with the most absorbance at 450  nm were sent for 
sequencing.
Expression and purification of VHH nanobody
The phage DNAs containing genes of the anti-CTGF/
CCN2 VHH camel antibody were amplified by PCR with 
two VHH-specific primers of Back-NcoI and forward-
NotI. After purified from agarose gel, an approximate 
400-bp fragment was obtained with flanked NcoI and 
Fig. 1 Schematics presentation of VHH library construction. cDNAs of A conventional antibody, B heavy chain antibody and their RT-PCR products 
of a and b. The VHH gene (b1) was obtained by another round of PCR






Table 2 The panning conditions for each round
Panning 
rounds






1st 3 × l011 0.1 2 5
2nd 4 × 1010 0.5 2 10
3rd 2 × 108 0.5 2 15
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NotI sites. The DNA was inserted into the pET22b vector 
for expression.
After transformed with pET22b-VHH-His, E. coli BL21 
cells were grown in 1L LB medium containing 100  μg/
ml ampicillin at 37  °C overnight. The culture was then 
added with isopropyl β-d-thiogalactopyranoside (IPTG) 
to a final concentration of 0.2  mM and incubated for 
another 12  h at 18  °C. Cells were collected after cen-
trifugation and then sonicated in rinse buffer (20  mM 
tris–HCl, 1  % Tritoon-X100, 1  mM DTT, 50  mM NaCl 
and 1 mM EDTA, pH 8.5) for 30 min at 300 W (1/1  s). 
The inclusion body were retrieved after centrifugation at 
15,000×g for 30  min, and then resuspended in dissolu-
tion buffer (20 mM tris–HCl, 6 M Guanine-HCl, 1 mM 
DTT, 200 mM NaCl and 1 mM EDTA, pH 8.5) followed 
by stirring overnight at 4  °C. The dissolved supernatant 
was retrieved and then subjected to Ni–NTA chromatog-
raphy according to the manufacturer’s manual. Finally, 
the target protein was eluted with elution buffer (2 mM 
Tris–HCl, 6  M Urea, 200  mM NaCl and 1  mM EDTA, 
pH 8.5). The protein samples during the expression and 
purification were analyzed with SDS-PAGE, and the con-
centration was determined by the Bradford method with 
a BCA kit.
Renaturation of the nanobody by three methods
The elution containing 6 M urea was serial diluted with 
ddH2O and then centrifuged at 8000 rpm. The urea criti-
cal concentration (Ct) was defined as the lowest urea 
concentration where protein aggregation occurred. 
Before the experiment, Blue Dextran 10 or calcein was 
added into the upper chamber to estimate the diffusion 
rate of big or small molecules, respectively. The flow rate 
and the urea addition were adjusted accordingly to avoid 
precipitation of unfolded protein. The next step of pro-
tein renaturation was carried out at 4  °C unless stated 
otherwise.
Dialysis–dilution method
The elution after Ni–NTA chromatography was diluted 
to containing 2.5 M urea and 1 or 0.1 mg/ml protein for 
the next renaturation. The renaturation was performed 
with a modified dialysis–dilution method using settings 
as shown in Fig. 2. A volume of 10 ml dilution containing 
0.1 or 1 mg/ml protein was added into the upper chamber 
while the lower chamber equipped with a magnetic rota-
tor was filled with renaturation buffer (1 M urea, 20 mM 
Tris–HCl, 0.5  mM PMSF, 0.4  M arginine, pH 7.4) and 
the between was placed with a 50  kD dialysis cellulose 
membrane. Renaturation buffer was continually pumped 
into the lower chamber at 2 ml/min. The upper chamber 
was added with 0.8 ml 8 M urea every 10 min to keep the 
urea concentration above the urea Ct concentration and 
Blue Dextran 10 (MW 10,000 kD) was added in the upper 
chamber as indicator. The renaturation buffer through 
the chamber was collected, stirred overnight and then 
subjected to another round of Ni–NTA chromatography 
as described above followed by desalting with ultra-filtra-
tion (6 kD filter). The insoluble was removed by centrifu-
gation and the final protein was lyophilized and stored in 
−20 °C for usage.
Normal dialysis method
The elution was diluted with 2 M urea to a final concen-
tration of 0.1 mg/ml protein. A volume of 10 ml dilution 
was stepwise dialyzed against 1.8, 1.6 or 1  M urea, and 
each concentration of urea was applied for 8  h. Aggre-
gates were removed by centrifugation and the soluble 
protein was finally desalted with ultra-filtration.
Normal dilution method
A baker equipped with a magnetic rotator was filled 
with 1 l renaturation buffer (1 M urea, 20 mM Tris–HCl, 
0.5 mM PMSF, 0.4 M arginine, pH 7.4). The elution was 
diluted with 2 M urea to a final concentration of 0.1 mg/
ml protein. A volume of 10 ml dilution was continuously 
pumped into the renaturation buffer at a constant rate of 
0.1 ml/min. The soluble protein was retrieved and finally 
desalted with ultra-filtration.
Circular dichroism spectrum
The elution after Ni–NTA chromatography was diluted 
with 2 M urea to a final concentration of 1 mg/ml pro-
tein while the protein samples after renaturation were 
dissolved in ddH2O at 1  mg/ml. The prepared samples 
were measured with a Jasco-810 spectropolarimeter 
(JASCO, Tokyo, Japan) using a 1-mm path-length quartz 
cell at 25  °C. Each data was collected as the average of 
four scans in the wavelength between 190 and 250  nm, 
with a 1 nm step resolution at 100 nm/min speeds. For a 
flexible peptide, the estimated percentages of secondary 
structure components should not be taken as absolute 
measures, but rather reflect on relative changes between 
spectra in a series of experiments.
Immunoreactivity assay by ELISA
The affinity of the purified VHH antibody with CTGF 
was evaluated by ELISA. The VHH or mouse anti-CTGF-
C mAb was immobilized onto a 96-well microtiter plate 
by adding 200  μg/ml ×  100  μl protein to each well fol-
lowed by an overnight incubation at 4 °C. The uncoupled 
protein was washed away and 100 μl 1 % BSA was added 
to block the uncoupled sites. The plate was incubated at 
37  °C for 2  h after 50  μl of CTGF ranging from 256 to 
0.125  μg/ml was added to each well. Afterwards, a vol-
ume of 50  μl  s antibody (1:4000 dilution, horseradish 
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peroxidase-conjugated mouse anti-human CTGF poly-
clonal antibody) was added. The plate was washed with 
2.0  % Tween-20/TBS before each round of addition. A 
volume of 50  μl 3,3′,5,5′-tetramethylbenzidine (TMB, 
Sangon, China) of 100 μg/ml was added to each well and 
incubated for 10 min. H2SO4 (1 M, 50 μl/well) was added 
and the plate was sent for colorimetry to measure the 
absorbance at 450 nm (Alisei, Italy).
Results
Construction of immunized VHH library
For construction of camel VHH library, a healthy Bac-
trian camel was immunized with purified CTGF-C over a 
period of 7 weeks. After the final immunization, the total 
IgG titer of immunized serum reached 1:12,800 indicat-
ing the success of raising immunogenic response in the 
camel. The RNA extracted from PBMC was analyzed by 
agarose gel and the result showed that there were major 
two binds (Fig. 3 lane 3). The antigen-binding gene frag-
ments of the heavy-chain antibody variable region were 
amplified from lymphocyte cDNA by nest PCR. In the 
first round of PCR amplified with primers CALL001 
and CALL002, the resulting PCR fragments had two dis-
tinct bands at around 700 and 900 bp corresponding to 
VH-CH1-CH2 and VHH-CH2 genes, respectively (Fig. 3 
lane 2). In the second nested PCR, only the VHH gene 
was retrieved with a size of ~400 bp (Fig. 3 lane 1).
According to the alignment (NCBI-blastx), the VHH 
DNA consisted of six regions: FR1 (1–60  bp), CDR1 
(61–90 bp), FR2 (91–138 bp), CDR2 (139–162 bp), FR3 
(163–201 bp) and CDR3 (202–303 bp). The VHH genes 
differed in 105 loci from the three CDR regions and the 
calculated repertoire reached over 1020.
Phage panning
The VHH repertoire was expressed on phages after res-
cuing with VCSM13 helper phages. The results of the 
phage ELISA visualised a strong enrichment of antigen-
specific clones during the consecutive rounds of pan-
ning (Table  3). The number of phage particles eluted 
from wells after each round was shown in Table  3 as 
well. Following three rounds of panning against CTGF, 
15 colonies were randomly chosen for sequencing. The 
sequencing results indicated there were ten different 
sequences and their amino acid sequences were shown in 
Fig. 4. Analyzed by alignment, the VHH consisted of five 
regions. The three frame regions were conserved while 
the CDRs differed greatly between each other. The tenth 
sequence confirmed by three sequencing results was 
used for protein expression.
Expression and purification of the nanobody
According to the deduced amino acid sequences, the 
expressed antigen-specific VHH nanobody was consisted 
of 135 amino acids with a theoretic M.W. of 14,464.12, 
and the pI was 7.84. The nanobody fused with a His-tag 
was mainly expressed as inclusion body and was retrieved 
by high affinity Ni–NTA column by denaturation method 
Fig. 2 The schematics of the dialysis–dilution cassette
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according to the manufacture manual. Sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
analysis showed that more than 75  % purity nanobody 
was obtained (Fig.  5). Moreover, the purified VHH was 
yielded on milligram quantity of 5.4  mg per liter of 
culture.
Renaturation of the nanobody by three different methods
Dialysis–dilution method
The elution after Ni–NTA chromatography containing 
6 M urea was diluted and then stored in 4 °C overnight. 
We found that the proteins within the dilutions would 
precipitate at urea concentrations below 2 M. So the urea 
Fig. 3 The retrieve of VHH mRNA and the DNA after each round of nested PCR. Lane M DNA marker; lane 1 the PCR products in the second nested 
PCR; lane 2 the PCR products in the first nest PCR; lane 3 the extracted mRNAs from the leukocytes
Table 3 The enrichment of the phage in during the bio-panning
NA undetected or unmeasured
a Loci where gene sequencing results indicating presence of different nucleotides
b The calculated size should be much greater than actually size due to gene coupling
library Input phage (pfu) Output (pfu) Gene polymorphism loci ina Calculated library sizeb
CDR1 CDR2 CDR3
VHH library NA NA 7 12 86 NA
1st panning 3 × 1010 1.36 × 105 3 8 15 6.71 × 107
2nd panning 4 × 109 3.19 × 106 NA NA NA NA
3rd panning 2 × 107 1.92 × 106 4 4 3 3072
Fig. 4 The alignment of the deduced protein sequences of 15 phage colonies after three rounds of bio-panning. The first sequence from the align-
ment was confirmed by three sequencing results. The second and the third were confirmed by two sequencing results
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critical concentration where proteins start to aggregate 
was determined as 2 M. The elution was therefore diluted 
to containing 2.5 M urea for renaturation.
Before the renaturation, 20 ml × 1 mg/ml Blue Dextran 
10 or 20  ml ×  2.5  M calcein was added into the upper 
chamber to estimate the diffusion rate of big or small 
molecules, respectively. The results indicated >96 % blue 
dextran 10 could diffused across the 50  kD membrane 
within 8 h while calcein could reached 45.7 % within 1 h 
(Fig. 6). Therefore, the renaturation of the VHH antibody 
was performed for 8 h and 0.8 ml × 8 M urea was added 
into the upper chamber every 10  min to maintain the 
urea concentration from the upper chamber. No appar-
ent precipitation had been observed during the dialysis 
when either 0.1 or 1 mg/ml startup protein samples were 
used. The protein after renaturation was well soluble in 
ddH2O and the size in SDS-PAGE gel was in consistent 
with before dialysis (Fig.  5). The recovery yield reached 
over 85 %.
Normal dilution and dialysis methods
The normal dilution method seemed very sufficient and 
yielded clear solution after dilution. However, the clear 
solution soon became cloudy after stored in 4  °C over-
night and TEM results indicated that there was a lot of 
particles present in the dilution (Additional file 1: Figures 
S1, S2). After removing the particles, the final recovery 
rate was about 13 %.
Fig. 5 The expression and purification of the VHH nanobody from E. coli. Lane M marker; lane 1 precipitates after cell lysis; lane 2 supernatant after 
cell lysis; lane 3 elution of Ni–NTA chromatography; lane 4 the VHH antibody renatured by the dialysis–dilution method; lane 5 the VHH antibody 
desalted by ultra-filtration
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Almost all proteins precipitated after normal dialysis 
and no further research was carried out to study the dial-
ysis method.
Circular dichroism spectrum
The results indicated the samples renatured by two dif-
ferent methods showed similar secondary structures that 
were 7  % alpha-helix and 45  % beta-sheet. The elution 
after chromatography dissolved in 2 M urea did not show 
apparent 2-D structures (Fig. 7).
Affinity and sensitivity detection
The activity of the nanobody recognizing CTGF was 
performed by ELISA and the results displayed that the 
OD450 value increased together with the concentra-
tions of the CTGF ranging from 0.125 to 128  μg/ml. In 
comparison with the commercial anti-CTGF-C mAb, the 
VHH antibody showed a superior CTGF-binding activity 
at the same weight concentrations (Fig. 8).
Discussion
Connective tissue growth factor (CTGF/CCN2), a mem-
ber of the CCN family, is a secreted protein with major 
roles in angiogenesis, chondrogenesis, osteogenesis, tis-
sue repair, cancer and fibrosis (Kapoor et al. 2008; Leask 
2008) Each module has specific binding affinity for cer-
tain proteins, such as fibronectin and heparin sulfate 
proteoglycans, extracellular signaling molecules, and 
cell surface proteins (Kubota and Takigawa 2015). The 
N-terminal domain (modules I and II) has been shown 
to mediate differentiation and collagen synthesis, and the 
C-terminal domain (modules III and IV) has been shown 
to regulate cell proliferation (Gao and Brigstock 2004; 
Hall-Glenn and Lyons 2011). A recently study showed 
that C-terminal domain of CTGF was associated with cell 
proliferation in leukaemia (Welch et al. 2015). It has been 
reported that the C-terminal domain of CTGF could 
stimulate cellular adhesion via the αv-β3 receptor (Ball 
et al. 2003; Hoshijima et al. 2006) and was involved in the 
fibrosis process (Rodrigues-Diez et al. 2015). Therefore, it 
is possible that the C-terminal domain of CTGF can be a 
potential novel pharmacological target of profibrotic dis-
ease such as using neutralizing antibodies, antisense oli-
gonucleotide and inhibitors.
Unlike a mouse which was usually sacrificed for lym-
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Fig. 6 The diffusion rate of the dialysis–dilution setting. a The diffu-
sion rate measured with Blue Dextran 10. A standard curve was made 
by preparing Blue Dextran 10 concentration serials and measuring 
with absorption at 620 nm. The Blue Dextran 10 was added into the 
upper chamber and dialyzed against the renaturation buffer. 100 μl 
samples were taken at different time points and measured with the 
absorption at 620 nm. The input flow rate at the lower chamber was 
2 ml/min. b The diffusion rate measured with Calcein. The exiting and 
emitting wavelengths were 495 and 515 nm, respectively, and the 






















Fig. 7 The secondary structure of the nanobody by circular dichro-
ism. The protein sample dissolved in 2 M urea did not show any 2-D 
structures. The protein samples after renaturation by dialysis–dilution 
or normal dilution method showed similar 2-D structures were 7 % 














Fig. 8 The CTGF-C binding affinity of VHH and mAb
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alive after this study and probably could be used in 
another experiment after immune homeostasis. After 
immunization with CTGF-C, the lymphocytes encod-
ing the anti-CTGF-C antibodies circulated in the blood 
vessel. We collected the peripheral blood and retrieved 
the lymphocytes for mRNA extraction. After reverse 
transcription and two rounds of PCR, the VHH library 
has been successfully constructed. Unlike unimmunized 
library, the phage titration in the first round of panning 
reaching 106  pfu/ml was much higher than previous 
reports implying the animal was well immunized and a 
lot of anti-CTGF-T-antibody expressed lymphocytes 
were present in the peripheral blood circulation (Tanha 
et  al. 2002; Miyazaki et  al. 2015). We applied two extra 
rounds of phage panning with extremely washing condi-
tion to screen the phenotype with the highest affinity to 
CTGF-C. The expressed VHH nanobody of 144 amino 
acids was much smaller than the mAb antibody which 
generally contained more than 500 residues. Therefore, 
as shown by the ELISA result, the VHH showed a supe-
rior CTGF-C-binding activity to mAb at the same mass 
concentration as there were much more VHH molecules 
than mAbs. The high affinity of the VHH nanobody could 
be attributed to two aspects: (1) low molecules weight 
resulting in less stereospecific blockade allowed more 
VHH molecules to target on one single CTGF-C protein; 
(2) extremely panning procedure resulted into the high-
est affinity of screened VHH nanobody.
The results showed the VHH antibody had been suc-
cessfully expressed as inclusion body in E. coli cells, and 
the VHH antibody fused with a His tag could be easily 
purified from the cell lysate with a purity over 75  % by 
Ni–NTA chromatography. After renaturation, the VHH 
antibody was subjected to another round of Ni–NTA and 
the result showed the purity was further improved. A 
purity over 90 % was obtained in the final product.
The inclusion body was renatured with a dialysis–dilu-
tion method. The dialysis cassette was specially designed 
for this method. The denatured VHH antibody was added 
into the upper chamber and then slowly diffused across 
the membrane which was totally different from the con-
ventional dialysis renaturation as shown in Fig.  9. The 
conventional dialysis and dilution methods were ineffec-
tive in our case and gave a total recovery of <5 and ~13 %, 
Fig. 9 Schematics of the dialysis–dilution method in comparison with the two conventional methods. The conventional dialysis was a time-con-
suming process allowing the protein to fold slowly into the correct form. The conventional dilution method was a time-saving process but always 
yielded misfolded products. The dialysis–dilution method combined the merits of both
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respectively. The protein refolding was a time-consuming 
process and the dialysis method taken hours gave enough 
time for proteins to refold. During the dialysis method, 
the protein was retained in the dialysis bag and the pro-
teins would start to refold while the denatured chemicals 
diffused outward. However, the dialysis was a compli-
cated and time-consuming method requiring numer-
ous repeats to optimize the refolding conditions and 
buffer composition, and generally taken multiple steps of 
dialysis (Jungbauer and Kaar 2007; Zilinskas and Serei-
kaite 2011; Berg et  al. 2012). As we known, during the 
protein refolding, the major obstruction came from the 
self-aggregation (Zilinskas and Sereikaite 2011; Gautam 
et al. 2012). Therefore, dilution was an effective method 
for in  vitro protein refolding as it allowed the protein 
to refold at a very low concentration thus to reduce the 
interference from self-aggregation (Gautam et  al. 2012). 
Our results demonstrated that the dialysis method was 
less effective than the dilution method. However, the 
dilution method was difficult to manipulate because 
the protein molecules needed to be separated into the 
solution instantly that required special equipment. Self-
aggregation was also reported as the major obstacle for 
the dilution method in many cases (Zilinskas and Serei-
kaite 2011; Gautam et  al. 2012). To our surprising, the 
nanobody did not precipitate instantly after misfolded 
by normal dilution method but form small nanoparticles. 
The modified dialysis–dilution method combined the 
merits of both. Firstly, proteins diffusing across the mem-
brane took hours allowed the protein to refold slowly into 
the correct form; secondly, the proteins diffused across 
the membrane as a single molecule therefore greatly 
reducing the self-aggregation. The CD results indicated 
the soluble proteins after different renaturation methods 
showed similar 2-D structures, suggesting that only well-
folded nanobody was soluble while the unfolded and mis-
folded proteins aggregated.
The anti-CTGF-C VHH antibody had been success-
fully expressed and purified from E. coli cells. The ELISA 
results indicated the VHH nanobody after renatura-
tion was bioactive and could specially bind CTGF with 
a superior affinity to mAb. The dialysis–dilution was a 
one-step, time-saving, economic and effective method, 
providing a promising alternative for industrial and labo-
ratorial application of protein renaturation.
Additional file
Additional file 1: Figure S1. The aggregated particles after normal dilu-
tion by dynamic light scattering. The protein samples immediately after 
normal dilution were diluted 100 times with PBS before sent for dynamic 
light scattering measurement. The results indicated there were numerous 
particles of several hundreds of nanometer in diameter. Figure S2. The 
aggregates after normal dilution by TEM.
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